Legochem Biosciences, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
2
Ending by 2030
Jun 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for Antibody-Drug Conjugate Comprising Antibody Against Human ROR1 and Use for the Same (US 11,707,533) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 1 fee due Feb 20, 2027The maintenance fee for Compounds Comprising Self-Immolative Group (US 10,383,949) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Compositions and Methods Related to ANTI-CD19 Antibody Drug Conjugates (US 11,827,703) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Sep 10, 2027The maintenance fee for Antibody-active agent conjugates and methods of use (US 10,583,197) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for Antibody-Drug Conjugates Comprising Branched Linkers and Methods Related Thereto (US 11,975,076) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,178,525 | FXA inhibitors with cyclic amidoxime or cyclic amidrazone as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,242,113 | Oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone pharmaceutical compositions thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,754,210 | Method for preparing 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl) derivative and intermediate used therein In force · From the USPTO record | In force | From the USPTO record | |
| US 8,703,939 | Method for preparing (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(substituted methyl)oxazolidin-2-one derivatives In force · From the USPTO record | In force | From the USPTO record | |
| US 9,669,107 | Antibody-active agent conjugates and methods of use In force · From the USPTO record | In force | From the USPTO record | |
| US 10,583,197 | Antibody-active agent conjugates and methods of use In force · From the USPTO record | In force | From the USPTO record | |
| US 9,988,372 | Crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition comprising same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,919,057 | Compounds Comprising Self-Immolative Group In force · High confidence | In force | High confidence | |
| US 9,993,568 | Compounds Comprising Self-Immolative Group In force · High confidence | In force | High confidence | |
| US 10,383,949 | Compounds Comprising Self-Immolative Group In force · High confidence | In force | High confidence |
Also on record, not counted in the 24: 7 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 pending · 1 abandoned · 6 no status recorded